Robert Barish
Gastroenterology · Ocala, FLNPI 1538197165
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,737 of the $4,654 with a category attached, or 80.3%. 22 manufacturers reported payments, led by Madrigal Pharmaceuticals at 28.9% of the total. 2025 is the largest year on record at $2,013, 3.4 times the $590 reported in 2019.
Across 108 payments — averaging $43.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$1K
- AbbVie$1K
- Boston Scientific$483
- Novo Nordisk$306
- Ipsen Biopharmaceuticals, Inc$217
- Gilead$179
- plus $889 from 16 others
Across 371 payments — averaging $3845.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$932K
- Madrigal Pharmaceuticals$170K
- Boehringer Ingelheim International GmbH$131K
- Boehringer Ingelheim$101K
- Bausch Health US, LLC$29K
- Gilead$18K
- plus $47K from 4 others
What the payments were for
- Travel & lodging$85218%
- Food & beverage$3,73780%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 10 | $1,345 |
| AbbVie | 55 | $1,234 |
| Boston Scientific | 4 | $483 |
| Novo Nordisk | 4 | $306 |
| Ipsen Biopharmaceuticals, Inc | 2 | $217 |
| Gilead | 4 | $179 |
| Medtronic | 2 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $136 |
| Phathom Pharmaceuticals, Inc. | 1 | $112 |
| Lilly USA, LLC | 1 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $75 |
| Intercept Pharmaceuticals, Inc. | 4 | $71 |
| Ironwood Pharmaceuticals, Inc | 3 | $49 |
| Pfizer | 3 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| UCB, Inc. | 2 | $33 |
| Beigene USA, Inc. | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Merck | 1 | $18 |
| Shionogi Inc | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $13 |
| Pharming Healthcare, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,654 in reported general payments places this provider in the 60th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Ocala
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.